Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI) announced its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01, Zacks reports.

Vivani Medical Trading Up 0.4%

VANI opened at $0.99 on Friday. The firm has a 50 day moving average of $1.19 and a two-hundred day moving average of $1.24. The firm has a market capitalization of $89.03 million, a PE ratio of -3.08 and a beta of 2.51. Vivani Medical has a 12-month low of $0.80 and a 12-month high of $1.66.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen lowered shares of Vivani Medical from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.75.

Vivani Medical Company Profile

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.